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Abstract
Many vaccines have been developed from live attenuated forms of bacterial pathogens
or from killed bacterial cells. However, an increased awareness of the potential
for transient side-effects following vaccination has prompted an increased emphasis
on the use of sub-unit vaccines, rather than those based on whole bacterial cells.
The identiﬁcation of vaccine sub-units is often a lengthy process and bioinformatics
approaches have recently been used to identify candidate protein vaccine antigens.
Such methods ultimately offer the promise of a more rapid advance towards pre-
clinical studies with vaccines. We have compared the properties of known bacterial
vaccine antigens against randomly selected proteins and identiﬁed differences in the
make-up of these two groups. A computer algorithm that exploits these differences
allows the identiﬁcation of potential vaccine antigen candidates from pathogenic
bacteria on the basis of their amino acid composition, a property inherently associated
with sub-cellular location. Copyright  2003 John Wiley & Sons, Ltd.
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Introduction
During the past 200 years the use of vaccines
to control infectious diseases caused by bacterial
pathogens has generally proved to be both effec-
tive and safe (Poland, 1999; Wilson and Mar-
cuse, 2001). Many of these vaccines were dis-
covered using an empirical approach (Nilsson,
2002) and included live attenuated forms of bacte-
rial pathogens, killed bacterial cells and individual
components of the bacterium (sub-units). Although
many bacterial vaccines are still widely used, a shift
towards reliance on antibiotics for the control of
infectious diseases occurred during the latter half
of the twentieth century.
The recent appearance of antibiotic resistant
strains of many bacterial pathogens (Gould, 2002;
Russell, 2002) has prompted a resurgence of inter-
est in the use of vaccines to prevent disease.
However, some vaccines are not considered to
offer appropriate levels of protection against infec-
tion and there are still many infectious diseases
for which effective vaccines are not available
(Plotkin, 2001; Poland et al., 2002). In addition,
an increased awareness of the potential for tran-
sient or longer-term side-effects following vacci-
nation (Plotkin, 2001; Wilson and Marcuse, 2001)
has prompted an emphasis on the use of sub-unit
vaccines.
Whilst empirical approaches to the selection of
vaccine sub-units are still employed, bioinformatics
approaches to select candidate protein sub-units
from bacterial genome sequences have been used
more recently (De Groot et al., 2001; Gomez
et al., 2000; Montgomery, 2000; Nilsson, 2002;
Pizza et al., 2000; Ross et al., 2001; Smith, 1996;
Wizemann et al., 2001). These approaches can be
used to screen genomes for potential candidates far
more rapidly than empirical approaches and have
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been termed ‘reverse vaccinology’ (Gomez et al.,
2000; Rappuoli, 2001).
Generally ‘in silico’ approaches to the identi-
ﬁcation of vaccine antigens have relied on the
assumption that candidate proteins will be located
on the outer surface of, or exported from, the bac-
terium. Amino acid composition has been shown
to be useful in the prediction of the sub-cellular
location of proteins (Feng, 2002). Some work-
ers have identiﬁed open reading frames (ORFs)
that encode proteins possessing a signal sequence
and screened this dataset to exclude proteins
with transmembrane domains (Gomez et al., 2000;
Pizza et al., 2000), and to include proteins with
lipoprotein attachment sites (Chakravarti et al.,
2000; Gomez et al., 2000) or other motifs asso-
ciated with cell surface anchoring (Pizza et al.,
2000; Ross et al., 2001). Other programs have
been used to predict epitopes that bind to T
cell receptors or major histocompatibility com-
plexes to assist in vaccine design and develop-
ment (Bond et al., 2001; Grandi, 2001; Mallios,
1999, 2001; Savoie et al., 1999). Whilst these
various approaches have yielded novel sub-unit
vaccines, the predictive power of these meth-
ods may be limited by our knowledge of protein
export and processing pathways in different bacte-
rial species, by the assumption that vaccine anti-
gens will be surface-located and by our limited
knowledge of the molecular architecture of outer
membrane proteins.
We have set out to investigate whether the bio-
physical properties of reported protein vaccine anti-
gens are signiﬁcantly different from a representa-
tive control protein dataset.
Materials and methods
Construction of vaccine antigen dataset
Bacterial vaccine antigens were identiﬁed by patent
and literature searches. To qualify for inclusion, the
candidate, whole or part of the protein or corre-
sponding DNA must have been shown to induce a
protective response in an appropriate animal model
after immunization. The amino acid sequences of
the vaccine antigens were obtained from pub-
licly available sequence databases, primarily from
the National Centre for Biotechnology Information
(http://www.ncbi.nlm.nih.gov).
Construction of control dataset
A control dataset was constructed that mirrored
the vaccine antigen dataset with respect to the
proportion of entries from each genus. For each
entry in the vaccine antigen dataset we ran-
domly selected 35 proteins from the proteome
of a representative species from the same genus.
Where possible, the same species from the vac-
cine antigen dataset was used for the control
dataset. In cases where an appropriate genome
sequence was available but had not been anno-
tated, the proteome was predicted using Glim-
mer, a system for ﬁnding genes in microbial DNA
(http://www.tigr.org/software.glimmer) (Delcher
et al., 1999). Where no completed genome se-
quence was available for any member of the genus
represented in the vaccine antigen dataset, all of the
known proteins from a chosen species were down-
loaded from the publicly available protein sequence
database (NCBI) and 35 proteins were then ran-
domly selected.
Removal of signal sequences
Known signal sequences of vaccine antigens were
removed from entries in the vaccine antigen
dataset. Proteins without a reported signal sequ-
ence, and all proteins in the control datasets, were
separated into Gram-negative and Gram-positive
entries and analysed using SignalP (Nielsen et al.,
1997); (http://www.cbs.dtu.dk/services/SignalP).
Predicted signal sequences were removed to create
two further datasets on which all comparisons of
the vaccine antigen and control datasets were done.
Construction of sub-cellular location protein
datasets
A search of the SWISSPROT database (Swiss
Institute of Bioinformatics; http://www.expasy.ch/
sprot; Bairoch and Apweiler, 2000) identiﬁed pro-
teins with deﬁned sub-cellular locations for each of
the bacterial species used to construct the control
dataset. No entries were available in SWISSPROT
for Corynebacterium diptheriae,s oCorynebac-
terium glutamicum proteins were used instead.
Any entries where the sub-cellular location of
the protein was listed as ‘putative’, ‘by similar-
ity’ or ‘suggested’ were omitted from the datasets.
Separate datasets were constructed for each sub-
cellular location, producing cytoplasmic (736 pro-
teins), inner membrane (265 proteins), periplasmic
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(77 proteins), outer membrane (99 proteins) and
secreted proteins (94 proteins).
Analysis of physical properties of proteins in
the control and vaccine antigen datasets
Predicted molecular weights and predicted isoelec-
tric points (pI) of proteins were calculated. Each
protein in the control and vaccine antigen datasets
was scored for hydrophobicity (Kyte and Doolittle,
1982), ﬂexibility (Bhaskaram and Ponnuswamy,
1988), bulkiness (Zimmermann et al., 1968) and
relative mutability (Dayhoff et al., 1978). The sta-
tistical signiﬁcance of any differences was calcu-
lated by the Mann–Whitney test (Mann and Whit-
ney, 1947; Wilcoxon, 1945). For all analyses, a p
score of <0.05 was considered to be signiﬁcant.
Calculation of amino acid composition of
control and vaccine antigen datasets
The percentage amino acid composition of every
protein was calculated. Statistically signiﬁcant dif-
ferences in amino acid composition between the
control and vaccine antigen datasets were calcu-
lated by the Mann–Whitney test (Mann and Whit-
ney, 1947; Wilcoxon, 1945).
Development of scoring algorithms
The amino acid composition of each dataset was
calculated as described above and the statistically
signiﬁcant differences noted. A score table was
then produced, based on these differences. Each
amino acid score was calculated using the mean
dataset scores, as follows:
Amino acid score =
% Composition of % Composition
vaccine antigen − of control
dataset dataset

% Composition of control dataset/10
Amino acids more frequently found in the vac-
cine antigen dataset compared against the con-
trol dataset received a positive score, while those
depleted in the vaccine antigen dataset received a
negative score. Those that showed no statistically
signiﬁcant difference between the two datasets
scored 0.
The scoring scale devised from the above analy-
sis was used to score proteins in the vaccine antigen
and control datasets as follows:
Protein score =
 Amino acid scores
Number of amino acids
in the protein
The vaccine antigen scoring scale was applied
to proteins from the sub-cellular datasets and the
predicted proteome of Streptococcus pneumoniae
strain R6 (Hoskins et al., 2001).
Construction of histograms
The distributions of scores from dataset compar-
isons are represented as histograms. Proteins from
each of the two datasets being compared (a query
dataset and a control) were scored according to
published scales (for hydrophobicity, ﬂexibility,
bulkiness and relative mutability) or using the
scales generated from amino acid sequences, as
described previously. The scores from the query
and control datasets were then combined and
ranked. The range of scores generated was divided
into 25 equal parts (histogram bins) that were used
to represent the x axis of the histogram. The upper
limit of each bin is used as the axis label. The y
axis shows the percentage of proteins from each
dataset that lies within each range of scores.
Results
Composition of the vaccine antigen and control
dataset
In total, 72 non-homologous vaccine antigens were
identiﬁed, originating from 32 bacterial species
in 23 genera (Table 1) with 26 originating from
Gram-positive bacteria and 46 from Gram-negative
bacteria (for the purposes of this study, mycobac-
teria were treated as Gram-positive bacteria). A
control dataset of 2520 proteins was constructed
by randomly selecting 35 proteins from each rep-
resentative species for each entry in the vaccine
antigen dataset (Table 2). The size of the con-
trol dataset was selected so that it was approxi-
mately the number of proteins encoded by a typ-
ical bacterial genome. These vaccine antigen and
control datasets were used for all subsequent com-
parisons. Of the proteins in the vaccine antigen
dataset, 52(72%) were identiﬁed as having signal
Copyright  2003 John Wiley & Sons, Ltd. Comp Funct Genom 2003; 4: 468–478.Analysis of known bacterial vaccine antigens 471
Table 1. Proteins used to construct the vaccine antigen dataset
Species Antigen Accession No.
Bacillus anthracis Protective antigen (PA) P13432
Bordetella pertussis Pertussis toxin S1 sub-unit CAB51543
Bordetella pertussis Filamentous haemagglutinin (FHA) S21010
Bordetella pertussis Pertactin (P69) CAB40080
Borrelia burgdorferi Outer surface protein A (OspA) S71533
Borrelia burgdorferi Outer surface protein B (OspB) CAA32580
Borrelia burgdorferi Outer surface protein C (OspC) S70290
Borrelia burgdorferi Virulent strain-associated repetitive antigen A (VraA) NP 045547
Borrelia burgdorferi Outer membrane porin protein (Oms66/p66) CAA61034
Borrelia burgdorferi Decorin binding protein A (DbpA) AAD05353
Brucella abortus Cu/Zn superoxide dismutase A33893
Brucella abortus 50S Ribosomal protein L7/L12 P41106
Brucella melitensis Outer membrane protein 25(Omp25) AAB06701
Campylobacter jejuni Flagellin (FlaA) AAF05902
Chlamydia trachomatis Major outer membrane protein (MOMP) P23732
Clostridium difﬁcile Toxin A P16154
Clostridium perfringens α-Toxin (phospholipase C) AAF20094
Clostridium perfringens ε-Toxoid (type D) CAB60614
Clostridium tetani Tetanus toxin AAF73267
Corynebacterium Pseudotuberculosis Phospholipase D CAA01541
Escherichia coli Heat-labile enterotoxin (B sub-unit) BAA25726
Escherichia coli Adhesin (FimH) AAC77276
Haemophilus inﬂuenzae Fimbrin (P5) P45996
Haemophilus inﬂuenzae Outer membrane protein P1 AAF97552
Haemophilus inﬂuenzae Outer membrane protein P6 P10324
Helicobacter pylori Cytotoxin-associated antigen(CagA) AAD07614
Helicobacter pylori Heat shock protein 10 (Hsp10) AAD07081
Helicobacter pylori Neutrophil-activating protein A (NapA) AAF37843
Helicobacter pylori Citrate synthase (GltA) AAD07097
Helicobacter pylori Urease (UreB) BAA78630
Helicobacter pylori Vacuolating cytotoxin (VacA) AAD07935
Helicobacter pylori Catalase NP 223527
Legionella pneumophila Major secretory protein (MSP) P21347
Legionella pneumophila Heat shock protein 60 (Hsp60/MCMP) P26878
Legionella pneumophila Outer membrane protein S (OmpS) A42596
Listeria monocytogenes Listeriolysin-O (LLO) AAF64524
Listeria monocytogenes Major extracellular protein (P60) P21171
Mycobacterium avium 65 kDa protein AAA99670
Mycobacterium bovis MPB83 Q10790
Mycobacterium bovis BCG Antigen 85A (Ag85A) CAA37206
Mycobacterium bovis BCG Antigen 85B (Ag85B) P12942
Mycobacterium tuberculosis Phosphate transport receptor PstS-3 (Ag88) CAA88138
Mycobacterium tuberculosis Catalase-peroxidase (KatG) CAB10056
Mycobacterium tuberculosis Antigen MPT63 P97175
Mycobacterium tuberculosis Early secretory antigen target 6 (ESAT-6) CAA17967
Neisseria meningitidis Neisseria surface protein A (NspA) AAD53279
Neisseria meningitidis Transferrin binding protein (TbpA) AAF81744
Pasteurella multocida Pasteurella multocida toxin (PMT) P17452
Pseudomonas aeruginosa Outer membrane protein F (OprF) AAG05166
Pseudomonas aeruginosa Pseudomonas exotoxin A (PEA) AAB59097
Pseudomonas aeruginosa PcV NP 250397
Rickettsia conorii Outer membrane protein A (OmpA) Q52657
Rickettsia rickettsii Outer membrane protein B (OmpB) Q53047
Rickettsia rickettsii Outer membrane protein A (OmpA) P15921
Rickettsia tsutsugamushi MBP-Bor56 protein AAA26375
Shigella dysenteriae Shiga toxin sub-unit B P08027
Staphylococcus aureus Penicillin-binding protein (MecA) BAB72132
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Table 1. Continued
Species Antigen Accession No.
Staphylococcus aureus Fibrinogen binding protein CAA79304
Staphylococcus aureus Collagen adhesin A42404
Staphylococcus aureus Recomb SEA lacking superantigenic activity P13163
Streptococcus agalactiae Surface immunogenic protein (Sip) AAG18478
Streptococcus pneumoniae Pneumococcal surface protein A (PspA) AAC62252
Streptococcus pneumoniae PhpA AAK26629
Streptococcus pneumoniae Pneumolysin A28568
Streptococcus pneumoniae Pneumococcal surface antigen A (PsaA) AAF0668
Streptococcus pyogenes Fibronectin binding protein (SfbI) S54418
Treponema pallidum Glycerophosphodiester phosphodiesterase (Gpd) AAB81591
Treponema pallidum Surface antigen 4D P16665
Treponema pallidum TmpB antigen F71283
Treponema pallidum TprK AAF45141
Yersinia pestis F1 capsule antigen CAA43966
Yersinia pestis V antigen AAC62574
sequences. A lower proportion (253 of 2520; 14%)
of proteins in the control dataset were predicted as
having signal sequences.
Physical properties of proteins in the vaccine
antigen and control datasets
The isoelectric points (pI) and molecular weights
were predicted for all proteins in the vaccine
antigen and control datasets. The results were
ranked and the distributions displayed as his-
tograms (Figure 1a, b). The two-peak pattern of
pI values seen with both the control and positive
datasets was also seen with the predicted proteomes
analysed from Escherichia coli, Mycobacterium
tuberculosis, Neisseria meningitidis and Strepto-
coccus pneumoniae (data not shown). The median
values for each dataset were calculated and the
Mann–Whitney test was applied. A comparison of
positive and control datasets revealed statistically
signiﬁcant differences for both molecular weight
and pI.
Amino acid composition of vaccine antigen and
control datasets
We analysed the amino acid compositions of the
proteins in the vaccine antigen and control datasets
using scales for hydrophobicity, ﬂexibility, bulki-
ness or relative mutability, according to previously
reported scoring methods (Bhaskaram and Pon-
nuswamy, 1988; Dayhoff et al., 1978; Kyte and
Doolittle, 1982; Zimmermann et al., 1968). The
output from each of these analyses was displayed
Table 2. Data sources of proteins used to construct the
control dataset
Genus Data type and species Data source
Bacillus Proteome of subtilis NCBI1
Bordetella Genome of pertussis Sanger Centre2
Borrelia Proteome of burgdorferi TIGR3
Brucella Proteins from melitensis NCBI
Campylobacter Proteome of jejuni Sanger Centre
Chlamydia Proteome of pneumoniae TIGR
Clostridium Genome acetobutylicum Genome
Therapeutics4
Corynebacterium Genome of diptheriae Sanger Centre
Escherichia Proteome of coli 0157 University of
Wisconsin5
Haemophilus Proteome of inﬂuenzae NCBI
Helicobacter Proteome of pylori TIGR
Legionella Proteins from pneumophila NCBI
Listeria Proteome of monocytogenes NCBI
Mycobacterium Proteome of tuberculosis Sanger Centre
Neisseria Proteome of meningitidis Sanger Centre
Pasteurella Proteome of multocida NCBI
Pseudomonas Proteome of aeruginosa NCBI
Rickettsia Proteome of prowazekii NCBI
Shigella Proteins from sonnei NCBI
Staphylococcus Proteome of aureus Sanger Centre
Streptococcus Proteome of pyogenes University of
Oklahoma6
Treponema Proteome of pallidum TIGR
Yersinia Proteome of pestis Sanger Centre
Proteins were selected from existing databases as shown:
1 http://www.ncbi.nlm.nih.gov; 2 http://www.sanger.ac.uk;
3 http://www.tigr.org; 4 http://www.genomecorp.com;
5 http://www.genome.wisc.edu; 6 http://www.genome.ou.
edu/. Where a genome was used, the proteome was predicted using
Glimmer. Where neither proteome or genome data was available,
proteins for the selected species were randomly chosen from the
NCBI protein database.
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Figure 1. Vaccine antigen and control databases scored by predicted pI and molecular weight. Histograms are shown
of the scores obtained by analysing the vaccine antigen and control databases for: (a) predicted molecular weight and
(b) predicted pI. Histograms are constructed as described in Methods
as a histogram (Figure 2a–d). The difference in the
distribution of the scores from the positive and con-
trol datasets was statistically signiﬁcant for each
scale.
Development of scoring algorithm
Although differences of the vaccine antigen and
control datasets using the various published scales
were statistically signiﬁcant, the separation of dis-
tribution was poor, with a high percentage of one
dataset falling within 1 SD of the mean of the other
dataset (Table 3). We have devised a scoring sys-
tem based on the average amino acid composition
of all of the proteins in the positive and control
datasets (Table 4). This scoring table was used to
score individual proteins in the vaccine antigen and
control datasets and the results of this analysis dis-
played as a histogram (Figure 3). A comparison of
the positive and control datasets scored this way
was statistically signiﬁcant and a difference in the
distribution of the scores was also seen with only
around 18% of one dataset falling within 1 SD of
the mean of the other dataset (Table 3).
Vaccine scoring algorithm applied to other
datasets
We considered that the differences in amino acid
composition of the vaccine antigen and control
Table 3. Separation of distributions between vaccine
antigen and control datasets using different scales
Proteins with scores
within 1 SD of mean
score of control
dataset
Proteins with scores
within 1 SD of mean
score of positive
dataset
Scale
used
Control
(%)
Positive
(%)
Control
(%)
Positive
(%)
pI 58.3 54.2 53.3 65.3
Mol wt 78.1 68.1 99.0 87.5
Hydrophobicity 75.8 73.6 57.0 73.6
Mutability 74.3 52.8 59.6 69.4
Flexibility 76.7 76.4 57.6 79.2
Bulkiness 75.6 54.2 38.2 68.1
Our algorithm 73.5 18.1 18.2 70.8
For each scale listed the percentage of scores in each dataset that falls
within 1 SD of the mean of the control database or of the vaccine
antigen database is given.
datasets might reﬂect the differences in the likely
cellular locations of the proteins. Therefore we
applied the scoring algorithm to groups of pro-
teins with known cellular locations (cytoplas-
mic, inner membrane, periplasmic, outer mem-
brane or secreted) and compared each sub-cellular
dataset against both the vaccine antigen and con-
trol datasets. There was no signiﬁcant difference
between the scores of known bacterial vaccine anti-
gens and the scores of outer membrane or secreted
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Figure2.Vaccineantigenandcontroldatabasesscoredbyfourdifferentscales.Histogramsareshownofthescoresobtained
by scoring the vaccine antigen and control databases with: (a) Kyte–Doolittle hydrophobicity scale; (b) Zimmermann et al.
bulkiness scale; (c) Bhaskaran and Ponnuswamy ﬂexibility scale; and (d) Dayhoff et al. relative mutability scale. Histograms
are constructed as described in Methods
proteins Table 5. The control dataset showed no
bias to any one sub-cellular location.
Vaccine scoring algorithm applied to a test
proteome
To evaluate the algorithm, we analysed the pro-
teome of S. pneumoniae R6 (2043 proteins) and
ranked the proteins by score. The vaccine antigen
database contains four entries from S. pneumoniae.
When ranked, pneumococcal surface protein A
(PspA), was the highest ranked (10th) of these
four known protective antigens, with the other
three vaccine antigens ranking within the top 10%
(within the ﬁrst 204 proteins when ranked by
score; Table 6). Potential vaccine candidates from
S. pneumoniae N4 (Wizemann et al., 2001), and
known pneumococcal virulence factors that may
also have potential as vaccine antigens (Jedrze-
jas, 2001) were also found within the top 10%
of proteins when ranked by our scoring algorithm.
Of the ﬁve proteins identiﬁed by Wizemann et al.,
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Table 4. Amino acid composition of vaccine antigen and
control databases
Vaccine antigen Control
Amino
acid Mean SD Mean SD p Score
A 9.39 4.13 8.41 4.21 0.039 1.17
C 0.60 0.81 1.12 1.23 0.000 −4.64
D 6.17 2.19 5.21 2.20 0.000 1.84
E 6.22 3.53 6.05 2.80 0.385 0
F 3.17 1.52 4.39 2.56 0.000 −2.78
G 8.36 3.21 6.93 3.13 0.000 2.06
H 1.63 1.47 2.14 1.51 0.000 −2.38
I 5.08 2.02 7.16 3.41 0.000 −2.91
K 7.48 3.92 6.41 3.87 0.040 1.67
L 7.46 2.20 10.06 3.29 0.000 −2.58
M 1.60 1.13 2.43 1.32 0.000 −3.42
N 6.24 2.64 4.50 2.61 0.000 3.87
P 3.68 2.04 3.83 2.08 0.295 0
Q 3.77 1.83 3.67 2.01 0.305 0
R 3.18 2.01 5.19 3.14 0.000 −3.87
S 6.99 2.92 6.25 2.39 0.052 0
T 7.27 3.19 5.04 2.10 0.000 4.42
V 6.99 2.09 6.84 2.66 0.396 0
W 1.18 1.04 1.01 1.02 0.109 0
Y 3.79 2.02 3.33 1.95 0.061 0
The mean percentage amino acid composition and SD of the proteins
within the vaccine antigen and control databases are listed. The
probability (p) of the two databases sharing the same median has
been calculated by the Wilcoxon Rank Sum test and is given to three
decimal places. Values of p below 0.05 are signiﬁcantly different and
have been allocated a score, as indicated in Methods.
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Figure 3. Vaccine antigen and control databases scored
by vaccine antigen scale. A histogram is shown of the
scores obtained by scoring the vaccine antigen and control
databases with the vaccine antigen scale. The histogram
constructed as described in Methods
Table 5. p Scores for comparisons of the vaccine antigen
and control datasets against datasets of various sub-cellular
locations
Probability of sharing
the same median with:
Dataset Positive dataset Control dataset
Cytoplasmic 6.8 × 10−30 1.5 × 10−10
Inner membrane 1.6 × 10−25 1.6 × 10−4
Periplasmic 2.0 × 10−5 2.1 × 10−21
Outer membrane 0.08 2.9 × 10−38
Secreted 0.33 1.3 × 10−35
The vaccine antigen scale was used to score proteins from either
the vaccine antigen or control dataset and datasets of proteins from
various cellular locations. The p score (the probability that two
datasets share the same median) was calculated by the Wilcoxon
Rank Sum test.
SP101, a conserved hypothetical protein with a sig-
nal peptidase II cleavage site motif, had the lowest
ranking of all vaccines and potential vaccine anti-
gens at 376 (Table 6).
Predicted signal sequences were removed from
the S. pneumoniae R6 proteome and ranked again
as described above. Slight changes in rankings
were observed; however, all but SP101 were again
found to rank within the top 10% (Table 6). Of
the top 100 pneumococcal proteins ranked by our
algorithm, 31 were predicted to possess a signal
sequence.
Discussion
The genome sequences of many bacterial pathogens
have now been determined and this has prompted
signiﬁcant work to investigate how these genome
sequences can be interpreted to provide improved
pre-treatments or therapies for disease. Previous
workers have used a range of methods to iden-
tify vaccine antigens. Some workers have assumed
that vaccine antigens are located on the surface of
the bacterium, and used algorithms that predict the
cellular location to interrogate the predicted bacte-
rial proteome for novel vaccine candidates (Gomez
et al., 2000). Others have used algorithms to locate
proteins with sequence homology to known vac-
cines (Adamou et al., 2001; Moxon et al., 2002).
Such techniques would fail to predict new fami-
lies of vaccine candidates. Other reported methods
involve the identiﬁcation of tandem repeats at the
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Table 6. Proteins of Streptococcus pneumoniae R6 scored
by the vaccine antigen scale
S. pneumoniae R6 Protein
Rank
SS
Score
SS
Rank
w/o
SS
Score
w/o
SS
Choline-binding protein G (CBP) 5 2.17 8 2.17
Surface protein pspA precursor∗
(CBP)†
10 1.96 12 2.04
Choline-binding protein A
(CBP)†
17 1.83 14 1.93
Choline-binding protein (CBP) 27 1.72 36 1.72
Choline-binding protein F (CBP)† 34 1.65 19 1.88
Autolysin (LytA) 79 1.28 86 1.28
ABC transporter protein–Mn
transport PsaA∗
81 1.26 88 1.26
Neuraminidase (NanB) 90 1.23 102 1.23
Hyaluronate lyase 122 1.11 134 1.11
Endo-β-N-acetylglucosaminidase
(CBP)—Sp46
139 1.05 150 1.05
Pneumolysin∗ 152 0.99 168 0.99
Pneumococcal histidine triad
protein A r PhpA∗
170 0.93 181 0.93
Neuraminidase (NanA) 183 0.89 193 0.89
Conserved hypothetical
protein—Sp101
376 0.55 385 0.55
Known vaccine antigens and virulence factors of Streptococcus
pneumoniae scored and ranked by the vaccine antigen scale are
listed. Proteins that are included in the vaccine antigen database
are denoted by∗. Proteins with Sp numbers are vaccine antigen
candidates, as identiﬁed by Weizman et al. (2001). CBP denotes
a choline-binding protein. † Predicted to have a signal sequence. SS,
proteome used inclusive of signal sequences; W/o SS, proteome used
with predicted signal sequences removed.
5  end of a gene, since such repeats have been
associated with some virulence genes (Hood et al.,
1996). However, many virulence-associated genes
lack such repeats and would not have been iden-
tiﬁed using this method. We have extended these
approaches to identify the likely properties of vac-
cine antigens by comparing the amino acid com-
position of known protein vaccine antigens with
those of randomly selected proteins in a control
dataset.
It has been a generally held hypothesis that
secreted or surface-located proteins are most likely
to induce a protective immune response (Grandi,
2001). In silico methods have therefore been
employed to identify potential vaccine antigens by
predicting secreted proteins by searching for signal
sequences (Chakravarti et al., 2000; Gomez et al.,
2000; Janulczyk and Rasmussen, 2001). Our anal-
ysis has conﬁrmed for the ﬁrst time that a higher
proportion of protein vaccine antigens have signal
sequences when compared to the control dataset
(72% vs. 14%).
Protein antigens having no classic leader
sequence would fail to be identiﬁed using methods
searching for signal sequences, such as ESAT-6
from M. tuberculosis (Li et al., 1999; Olsen et al.,
2001; Sorensen et al., 1995). Using our scoring
algorithm, ESAT-6 was ranked 92nd out of the
3918 proteins in the entire predicted proteome of
M. tuberculosis (i.e. in the top 3%).
The p scores of both predicted pI and molecular
weights of the proteins in the positive dataset
showed statistically signiﬁcant differences from the
control dataset. The bimodal pattern of the pI
values occurred with all of the datasets analysed
and conﬁrms previous observations with bacterial
and archaeal proteomes (Van Bogelen et al., 1999).
Since proteins are generally less soluble around
their isoelectric points, and the cytoplasm has a
pH value near to neutrality, it has been suggested
that cytoplasmic proteins rarely have a neutral pI.
Our analysis has revealed that the hydrophobic-
ity, bulkiness, ﬂexibility and mutability of vac-
cine antigens are signiﬁcantly different from these
properties of our control dataset. As most vac-
cine antigens previously described are surface-
exposed or secreted, they are more likely to be
in contact with surrounding media. This might be
reﬂected in their hydrophobicity and may there-
fore explain the differences seen between the two
datasets using hydrophobicity as a scale. The dif-
ference in mutability could reﬂect the ability of
pathogens to alter their antigenic presentation and
thereby evade the host’s immune system. Pheno-
typic variation in the relevant cell-surface pro-
teins has been seen amongst clinical isolates of
some species, suggesting that antigenic proteins can
mutate and evolve during the period of infection
(Peterson et al., 1995). This could also account for
the differences seen in the comparisons of bulk-
iness, molecular weights and ﬂexibility since the
use of small, ﬂexible residues on a protein surface
may also reﬂect the capability to mutate. The dif-
ference in molecular weight reﬂects the size ranges
of the two datasets. The control datasets ranges
from 1.62 to 252 kDa, whilst the vaccine antigen
dataset ranges from 7.69 to 367 kDa. The overlap
between the two datasets does not allow this prop-
erty to be used to predict vaccine antigen proteins.
The greatest difference in separation of distribution
between the vaccine antigen and control datasets
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was achieved when amino acid compositions were
compared. The algorithm we derived exploits these
differences.
Using Streptococcus pneumoniae R6 as a test
proteome, our scoring algorithm was able to rank
the known antigens included in our vaccine anti-
gen dataset within the top 10% of S. pneumoniae
proteins — other bacterial proteomes have also
been ranked using our scoring algorithm, and the
known vaccine antigens occur most frequently in
the top 10% of scores (data not shown). Other
virulence factors and potential vaccine candidates
from S. pneumoniae were also ranked within the
top 10% of scores.
This study demonstrates a fast and efﬁcient scor-
ing system that utilizes amino acid composition as a
tool for the prediction of vaccine candidates. Con-
struction of the vaccine antigen dataset has con-
ﬁrmed that a high proportion of known antigens
have signal sequences. Since this scoring system
is based on amino acid composition, secreted and
outer membrane proteins score highly using the
algorithm described. However, since this method
does not rely on sequence similarity or motifs,
it should also identify vaccine candidates lack-
ing such features that other prediction tools, using
these criteria, may miss. Ranking proteomes by this
method has shown that known protective antigens
score highly, independently of cellular location or
possession of signal sequences. In contrast to previ-
ous methods, our algorithm uses data derived only
from bacterial proteins and therefore is speciﬁc
for use with bacterial genomes. This scoring sys-
tem therefore provides a fast and efﬁcient method
of ranking whole bacterial proteomes for poten-
tial vaccine antigen candidates. We aim to use the
datasets and algorithms to predict novel vaccine
candidates from pathogenic bacteria that will form
the basis for clinical trials.
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